Practical Prediction of Ten Common Streptococcus pneumoniae Serotypes/Serogroups in One PCR Reaction by Multiplex Ligation-Dependent Probe Amplification and Melting Curve (MLPA-MC) Assay in Shenzhen, China

Lijuan Wu1,2*, Xiaomao Yin3*, Lei Zheng1, Jianhua Zou2, Ping Jin2, Yanwei Hu1, Timothy Kudinha4, Fanrong Kong5, Xu Chen2, Qian Wang1*

1 Laboratory Medical Centre, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China, 2 Clinical Laboratory, Bao’an Maternity and Child Health Hospital, Shenzhen, Guangdong Province, China, 3 Clinical Laboratory, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong Province, China, 4 Charles Sturt University, Leeds Parade, Orange, New South Wales, Australia, 5 Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research–Pathology West, Westmead Hospital, New South Wales, Australia

☯ These authors contributed equally to this work.
* nfyyWangQian@163.com

Abstract

Background
Streptococcus pneumoniae has more than 95 distinct serotypes described to date. However, only certain serotypes are more likely to cause pneumococcal diseases. Thus serotype surveillance is important for vaccine formula design as well as in post-vaccine serotype shift monitor. The goal of this study was to develop a practical screening assay for ten Shenzhen China common pneumococcal serotypes/serogroups in one molecular reaction.

Methods
A molecular assay, based on multiplex ligation-dependent probe amplification (MLPA) and melting curve (MC) analysis, was developed in an integrated approach (MLPA-MC) for the detection of ten capsular serotypes/serogroups 4, 6 (6A/6B/6C/6D), 9V/9A, 14, 15F/15A, 15B/15C, 18 (18F/18A/18B/18C), 19F, 19A and 23F. We designed serotype/serogroup-specific MLPA probes and fluorescent detection probes to discriminate the different serotypes/serogroups in one molecular reaction. The three steps of MLPA-MC assay are continuous reactions in one well detected by LightCycler 480. A total of 210 S. pneumoniae isolates from our local Maternity and Child Health Hospital were randomly chosen to evaluate the assay against published multiplex PCR assays.
Results
Our results showed that 198 (94.3%) of S. pneumoniae isolates were type-able by our assays and the results were in complete concordance with the published multiplex PCRs. Using the MLPA-MC assay, 96 S. pneumoniae isolates could be typed within 3 hours with limited hands-on time. This serotype/serogroup-screening assay can be easily modified or extended by modification of the serotype/serogroup-specific MLPA probes combinations according to the needs of different laboratories.

Conclusions
We recommend use of this assay as a starting point for screening serotype/serogroup frequencies. There is a need for this assay to be combined with other molecular typing assays, like published serotype specific PCRs, or even the Quellung reaction for serotype confirmation.

Introduction
Streptococcus pneumoniae accounts for about 1 million children deaths annually due to pneumonia and meningitis, mostly in developing countries [1]. The capsular polysaccharide represents an important virulence factor and characterizes S. pneumoniae into 95 distinct serotypes (within 46 serogroups). There are ten common serotypes/serogroups that account for most paediatric pneumococcal infections worldwide, with serogroups 6, 14, 19 and 23, the most common [2–5]. However, the distribution of serotypes can vary with age, geography and time [2, 6–9]. In China, two nation-wide studies on the distribution of S. pneumoniae serotypes in invasive pneumococcal diseases (IPD) and in children with pneumonia, showed that 19F, 19A, 23F, 6B and 14 were the most common serotypes, totally accounting for 73.1% of IPD and 87.9% of children with pneumonia [10, 11]. A study in Shenzhen city showed that these five serotypes (19F, 19A, 23F, 6B and 14), accounted for 81.6% of IPD in children[12].

The Quellung reaction or Neufeld test (conventional serotyping) is the gold standard for serotyping, but it’s too expensive for most developing countries including China [9, 10, 13, 14]. In addition, it’s labor-intensive and the interpretation of results is subjective and need expert training. Several different molecular assays have been developed as alternatives to serotyping, with most assays based on serotype-specific or serotype-associated sequences in the cps gene cluster, namely wzy and wzx, or cpsA-cpsB (wzg-wzh) [9, 15–17].

USA CDC have developed and published a sequential multiplex PCR scheme based on serotype specific PCRs to detect specific pneumococcal serotypes from isolates and directly from clinical specimens, which has been widely used [9]. Multiplex PCR-based methods offer a simple, flexible and economical approach for the surveillance of pneumococcal diseases, and also have the capacity to detect multiple serotypes in mixed serotype specimens. However, these developed schemes need sequential multiplex PCRs, and also gel electrophoresis for identifying PCR products [13, 18]. A single molecular reaction assay, which is rapid, easy and high-throughput and without a need for gel electrophoresis, is preferred for the many busy clinical diagnostic labs.

The multiplex ligation-dependent probe amplification (MLPA) technology uses a simple-to-perform multiplex PCR method, which is able to amplify up to 40 different targets simultaneously [19]. So far, MLPA has been used to detect infectious disease agents, specifically the
differentiation of 15 respiratory viruses [20], but has not been developed to identify bacterial
(in particular S. pneumoniae) serotypes. Based on the MLPA technology, and the product iden-
tification accomplished by the melting curve (MC) technology, it is highly possible that the dif-
ferent serotypes can be identified by unique melting peak analysis after MLPA reaction in one
single well.

The aim of this study was to develop a practical screening assay for ten commonest pneu-
mococcal serotypes/serogroups, in Shenzhen China, in one PCR reaction, as a show case to
highlight the potential utility of MLPA-MC technologies in molecular diagnostics. The study
targeted the most common five serotypes in Shenzhen China, three PCV7 vaccine serotypes/
serogroups (4, 9V/9A and 18C), and the emerging serotypes 15B/15C and 15F/15A[21], to
develop a multi-parameter molecular assay for screening serotypes of S. pneumoniae and evalu-
ated the assay on a set of paediatric clinical isolates.

Materials and Methods

Ethics Statement

The study protocol was approved by the Human Research Ethics Committee of Bao’an Matern-
ity and Child Health Hospital (No. S-2013002), and written consent was obtained from the
next of kin, caretakers, or guardians on behalf of the children enrolled in this study.

S. pneumoniae Isolates

Thirty-nine reference S. pneumoniae isolates, representing different serotypes, were used as a
control set to test MLPA-MC specificity and to determine cross-reactivity. They included sero-
types 4, 14, 6A, 6B, 6C, 6D, 9V, 9A, 15F, 15A, 15B, 15C, 18F, 18A, 18B, 18C, 19F, 19A, and
23F, which were related to the target serotypes/serogroups in this study. Other twenty sero-
types (1, 2, 3, 5, 8, 20, 7F, 7C, 9N, 9L, 10A, 11A, 11D, 12F, 17F, 22F, 22A, 23A, 23B and 33F)
that were not targeted in this study, were also included in but as negative controls. In addition,
5 to 10 known serotype isolates for each of the ten serotypes/serogroups targeted in this study
were used to access the probe sets. Finally, 210 additional pneumococcal isolates obtained from
children, including 30 invasive pneumococcal isolates (Jan 2009 to Jan 2012), and 180 induced
sputum source pneumococcal isolates (Jan 2012 to June 2012), from Bao’an Maternity and
Child Health Hospital, Shenzhen, China, were chosen for a double-blinded study to evaluate
the performance of the MLPA-MC assay against 3 multiplex PCRs selected from 8 USA CDC
sequential multiplex PCR assays which target the ten serotypes/serogroups in the study (http://
www.cdc.gov/streplab/pcr.html). All the 210 pneumococcal isolates were confirmed using
standard microbiological tests, including colony morphology, optochin susceptibility and bile
solubility.

DNA Extraction from Bacterial Isolates

Pneumococcal isolates were retrieved from storage by subculture on blood agar plates and
incubated overnight at 35°C in 5% CO₂. Genomic DNA was extracted from bacteria by using
the AxyGenamp DNA Mini Extraction Kit (Axygen, USA). Extraction was performed accord-
ing to the manufacturer’s instructions and the purified nucleic acid was diluted in a final vol-
ume of 100 μL Tris EDTA buffer and stored at -20°C until use.
MLPA Combined with Melting Curve Analysis (MLPA-MC) Probes Design

The MLPA probes were designed as described earlier[19]. Twelve pairs of MLPA probes were designed and included ten pairs of serotype/serogroup-specific (4, 6, 9V/9A, 14, 15A/15F, 15B/15C, 18, 19A, 19F and 23F) probes and two pairs of internal controls (cpsA and lytA). The internal controls were used as “catch-all” controls, as both are species-specific and found in almost all S. pneumoniae, except non-capsular isolates that lack cpsA. MLPA probes contained left and right probes. The left probe consisted of: (a) the universal forward primer binding site, and (b) serotype/serogroup specific left probe oligonucleotides (LPO); the right probe consisted of: (c) serotype/serogroup-specific right probe oligonucleotides (RPO), (d) the serotype/serogroup-specific stuffer sequence, and (e) the universal reverse primer binding site. Among them, the LPO (b) and RPO (c) hybridize specifically to template DNA. We specifically designed them against conserved gene within each serotype/serogroup, but with heterogeneity between targeted and the rest of the serotypes/serogroups. The specificities of LPO and RPO were checked and determines by blastn the serotype specific PCR products against GenBank database (http://www.ncbi.nlm.nih.gov), with $T_m$ near 70°C and without SNP. Each stuffer sequence (d) determined the specific detection of product, while the universal forward (a) and reverse (e) primer binding site of each MLPA probe is the same (forward primer binding sequence, 5'-GGGTTCCCTAAGGGTTGGA-3; reverse primer binding sequence, 5'-TCTAGATTGGATCTTGCGAC-3). The MLPA probe design is shown in Fig 1A.

The serotype/serogroup-specific fluorescent detection probe had the same sequence as the specific MLPA stuffer sequence, and each sequence, whose source was bacteriophage, was from the commercial respiratory virus diagnostic kit made by Pathofinder (http://www.pathofinder.com; The Netherland) with some minor modifications [20]. The twelve probes were labelled with ROX or CY5 fluorescence. Each probe had a specific $T_m$ for melting curve assay which was used as a marker to discriminate the different serotypes. It could be used repeatedly in different serotypes/serogroups panels. All the probes were synthesized by Invitrogen (Shanghai, China). The probes details are shown in Table 1.

MLPA-MC Reaction

MLPA reaction was performed essentially as described earlier [19], with some modifications. The three steps of MLPA-MC assay are continuous reactions in one well detected by LightCycler 480(Roche): A. Hybridization. The template DNA hybridize to specific MLPA probes. The mixture included 5 μL S. pneumoniae DNA sample, 1.5 μL probe mixture (0.5 fmol of each serotype specific MLPA probe in TE buffer; included all the 10 targeted serotypes/groups and cpsA and lytA probes), and 1.5 μL MLPA buffer (1.5 M KCl, 300 mM Tris-HCl, pH 8.5, 1 mM EDTA) in one well (8 μL total sample volume). Denaturation was performed for 10 min at 98°C and then the mixture incubated for 1h at 60°C for hybridization. B. Ligation and PCR. The hybridized mixture was subsequently diluted to 40 μL by addition of 32 μL ligation and PCR buffer. The 32 μL ligation and PCR reaction buffer contained the following: 2.5 mM MgCl$_2$, 10 mM Tris-HCl, 0.2 mM Nicotinamide Adenine Dinucleotide (NAD), deoxynucleoside triphosphates 0.2 mM each, 1 U Taq polymerase, 1 U heat-stable ligase 65 enzyme, 12 pmol fluorescent detection probes (12 probes included, 1 pmol each), 0.3 μM of the universal PCR primers (forward primer, 5’-GGGTTCCCTAAGGGTTGGA-3; reverse primer, 5’-GTGCCAGACATCCAT-(labeled FAM)CTAGA-3’. The ratio of forward and reverse primer was 1:2. FAM, Carboxyfluorescein). And by incubating 15 min at 54°C for ligation, the hybridized LPO and RPO are joined by ligase to an integral MLPA probe, followed by PCR amplification. The integral MLPA probes were amplified by an asymmetric PCR reaction with one universal primer.
**Fig 1. Overview of the MLPA-MC assay.** (A) Hybridization: A pair of MLPA probe consists of left and right probe: (a) Universal forward primer binding site (5'-GGGTTCCCTAAGGGTTGGA-3'), (b) Left probe oligonucleotides (LPO): Left serotype specific hybridization regions; (c) Right probe oligonucleotides (RPO): Right serotype specific hybridization regions, (d) Serotype specific stuffer sequence, (e) Universal reverse primer binding site (5'-TCTAGATTGGATCTTGCTGGCAC-3'). The LPO and RPO hybridize specifically to the target DNA sequences adjacent to each other. (B) Ligation and PCR: LPO and RPO joined by ligation enzyme. The linked MLPA probes are amplified by an asymmetric PCR reaction by one universal primer set. The PCR products consist of ds-DNA and ss-DNA. (C) MC analysis: Melting curve assay of the hybridized specific fluorescent detection probe and the ss-DNA of PCR products.

doi:10.1371/journal.pone.0130664.g001
| Target gene | GenBank no | start | Sequence of LPO | Sequence of RPO | Product size (bp) | Fluorescent detection probe |
|-------------|------------|-------|-----------------|-----------------|------------------|-----------------------------|
| wzy         | CR931635   | 9341  | GTTCACATCTACCTCTTGTCAGCTAGTTATCCGGATGCTGAGCCCTCGAG | GCAATAATTGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGCCAGGCTGATGGATAGCCGROX |
| wci         | CR931639   | 8806  | GAGTATGGGAAGGTGTTGTTCTGCCCTGAGCAACATTTGTATGAGC | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 119 | TCCGACAGCTTAAAGGACGCTCROX |
| 9V/9A       | CR931648   | 10676 | CCGTCGAGCAGATATCTGTATACGGATTTGGTATCTGGT | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 127 | TCCGACAGCTTAAAGGACGCTCROX |
| wzy         | CR931662   | 8002  | TCCTACTCCCTTGAGCAGTTAAGCATCTTCCAGTACCACTCCACCTCGAG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 109 | ACTGAGGAGAGTGGTCA |
| wzy         | CR931673   | 11488 | GTGGGTTGTTTTAGTGATTACAATGGGCTGTGCCTTCGTTTAGCACTTGGGTT | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 127 | AGCCAGAGCTTAAAGGACGCTCROX |
| wzy         | CR931678   | 11298 | CAGTGTTATGGATAGTGCTGATCGACGGGAGTTTCACTTACGCTATG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 130 | ATGATCCCTTAAAGGACGCTCROX |
| wzy         | CR931675   | 9672  | CAGTGTTATGGATAGTGCTGATCGACGGGAGTTTCACTTACGCTATG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 126 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931685   | 9085  | TAACTGGATTGGTACATCGCCGATTTGACGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 134 | AGCCAGAGCTTAAAGGACGCTCROX |
| wzy         | CR931663   | 7971  | GCCTGAGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7531  | GGATGGAGGAGTCTGTACGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931661   | 1459  | CTGGATGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 136 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7459  | CGATGGATGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 136 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7971  | GCCTGAGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7531  | GGATGGAGGAGTCTGTACGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931661   | 1459  | CTGGATGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 136 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7459  | CGATGGATGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 136 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7971  | GCCTGAGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7531  | GGATGGAGGAGTCTGTACGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931661   | 1459  | CTGGATGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 136 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7459  | CGATGGATGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 136 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7971  | GCCTGAGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7531  | GGATGGAGGAGTCTGTACGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931661   | 1459  | CTGGATGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 136 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7459  | CGATGGATGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 136 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7971  | GCCTGAGCTGATCGATGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGGAGTTATGGATATTCCGGATGCTCROX |
| wzy         | CR931662   | 7531  | GGATGGAGGAGTCTGTACGCTGATGCTGATGCTGATGCTGATGCTG | GGGGAGTTATGGATATTCCGGATGCTGAGCCCTCGAG | 135 | GGGGAGTTATGGATATTCCGGATGCTCROX |
primer set. The PCR amplification was as follows: an initial cycle of 2 min at 95°C, followed by 10 cycles of 30 s at 94°C, 30 s at 60°C, and 1 min at 72°C and 23 cycles of 30 s at 94°C, 30 s at 50°C, and 1 min at 72°C. The PCR products were ds-DNA and ss-DNA labeled with FAM.C. Melting Curve analysis (MC). Melting Curve analysis assay (MC) of the hybridized specific fluorescent detection probe and the ss-DNA of PCR products was performed as follows: Firstly, an initial denaturing step of 2 min at 95°C was carried out, which eliminated any non-specific binding, and then followed the specific binding of fluorescent detection probe and the ss-DNA labeled with FAM. The binding illuminates the ROX/CY5 according to fluorescence resonance energy transfer (FRET) and the melting peak is determined by the (d/dt) fluorescence from 45°C–85°C. The overall MC analysis time is about ten minutes. The overview of MLPA-MC is shown in Fig 1. All buffers and enzymes for MLPA-MC were obtained from Invitrogen (Shanghai, China). All clinical isolates (n = 210) were analyzed by MLPA-MC assay.

**Sensitivity, Specificity and Reproducibility of MLPA-MC**

Sensitivity of MLPA-MC assay was tested on serial dilutions of cloned DNA standards with a minimal threshold for detection set at 1000 copies for each probe in the panel. Serotype/serogroup-specificities of the specific probes were assessed by testing the control isolates. When the target control isolates were tested by MLPA-MC assay, the results showed three melting peaks, the serotype/serogroup specific peak, the cpsA, and ltyA peaks, as shown in Fig 2. For the other serotypes/serogroups (other than the 10 targeted serotypes/serogroups) isolates that were used as negative or specificity controls, only cpsA and ltyA peaks were obtained, as in Fig 3. The actual melting peak of each pair of probes fluctuated in the range of ±0–2 centigrade (°C) to the expected Tm, which was acceptable, as shown in Fig 4. No cross-reactivity among the ten target probes was observed when they were tested against the control set. Of the ten probes, five were specific for the target serotypes of 4, 14, 19F, 19A and 23F. For USA CDC specific mPCRs, the PCR primers can’t discriminate between serotypes 9V and 9A, 15B and 15C, 15F and 15A, four serotypes of serogroup 18 (18F/18A/18B/18C) and four serotypes of serogroup 6 (6A/6B/6C/6D), respectively. In this study, serotype 9V/9A probe reacted with both serotypes 9V and 9A; serotype 15F/15A probe reacted with both serotypes 15F and 15A; serotype 15B/15C probe reacted with both serotypes 15B and 15C; serogroup 18 probe can react with all 4 serotypes of 18F/18A/18B/18C; serogroup 6 probe can react with all 4 serotypes of 6A/6B/6C/6D. Reproducibility of our results depended on the purity of DNA samples and the thoroughness of mixing during the reactions.

**Multiplex PCR Reaction**

Ten USA CDC mPCR primer pairs were used to target serotypes/serogroups in this study. The sequences for the serotype(s)-specific primers, the PCR conditions and product detections are available at the USA CDC web page (http://www.cdc.gov/ncidod/biotech/strep/pcr.htm), which have also been described elsewhere[13, 18]. The primers were grouped into three multiplex reactions as below: reaction one included three primer pairs for serotype/serogroups 4, 6, and 18; reaction two included four primer pairs for serotype(s) 14, 9V/9A, 15F/15A, and 19A; and finally reaction three included three primer pairs for serotype(s) 15B/15C, 19F, and 23F. Additionally, a primer pair (primer cpsA-f and cpsA-r) was included in each reaction as an internal control. Each serotype in one reaction can be distinguished by a specific product size. The representative mPCR reactions are shown in S1 Fig.

All primers were synthesized by Invitrogen (Shanghai, China), whilst all PCR related enzymes, and other reagents were from Takara Bio (Dalian, China). All the 210 S. pneumoniae isolates were analyzed by the three multiplex PCR reactions.
Results

MLPA-MC Analysis of the Clinical Isolates

For the 210 clinical isolates, 198 (94.3%) isolates were clearly discriminated by one reaction MLPA-MC assay, and the actual melting peaks of each serotype fluctuated in the range of ±0~2 centigrade (°C) to the expected $T_m$. The isolates were discriminated into the following serotypes/serogroups; 19F (n = 67, 31.9%), 23F (n = 40, 19.1%), 19A (n = 22, 10.5%), 6 (n = 37, 17.6%), 15B/15C (n = 14, 6.7%), 14 (n = 13, 6.2%), 15A/15F (n = 2, 1.0%), 4 (n = 1, 0.5%), 18 (n = 1, 0.5%) and 9V/9A (n = 1, 0.5%). Twelve isolates (5.7%) were non-typeable by MLPA-MC assay. Further results are shown in Table 2.
The MLPA-MC assay identified the same serotype or group as that identified by mPCR in all 198 clinical isolates. Both MLPA-MC and mPCR failed to identify the serotypes of 12 isolates. Thus agreement of the MLPA-MC and mPCR was 100% for the clinical isolates. However, the MLPA-MC assay had a high throughput, with a batch of 96 reactions carried out in 3 hours. Consequently, the 210 MLPA-MC reactions were performed in 9 hours, with limited hands-on time. On the other hand, at least 400 mPCR reactions performed according to the mPCR scheme needed a total of 18 h of work. Besides PCR instrument, other additional requirements for the mPCR test included electrophoresis, Gel Imager and also needed more hands-on time. The comparison details are shown in Table 3.

**Discussion**

To our knowledge, this is the first study to determine the ten common serotypes/serogroups of *S. pneumoniae* using MLPA-MC assay in one PCR reaction. Both the serotype-specific MLPA probes and fluorescent detecting probes were the key of the MLPA-MC assay that determined
the specificity of the assay. Our study indicates that \textit{cps} serotype/serogroup-specific genes can also be targeted to efficiently and reliably determine serotype specific MLPA probes besides the PCR primers [9, 14, 17, 22, 23]. Compared to serotype specific PCR for the amplification of the target template DNA, the MLPA assay amplifies the MLPA probe itself [19]. The concentration of each serotype specific MLPA probe in the hybridization system is 10\textsuperscript{7} pmol/L, which is much higher than that of template DNA. The hybridization time is 1 hour in the system, which is enough for the bacteria genome though much longer (less than 16 h) is needed for human genome. The combination of the MC with MLPA for identification of the different products, was a modification of the traditional MLPA assay that made the assay more automatic, and simple for busy clinical diagnostic labs. As Table 3 shows, the MLPA-MC assay has advantages.
of both the mPCR and the real time PCR, with high throughput and continuous reactions in one well. The mPCRs combined with additional step of detection of products like gel electrophoresis, capillary electrophoresis, and reverse line blot microarrays have been used effectively in different studies [9, 13, 16–18, 24]. Real time PCR is more sensitive and automatic than mPCR for diagnosis and serotyping in children with culture negative pneumococcal invasive disease, but is limited by throughput [25].

The MLPA-MC assay successfully assigned 198 (94.3%) of the clinical isolates to the correct serotype/serogroup in total agreement to those from the mPCR reactions. The most common five serotypes (19F, 23F, 19A, 6, and 14) accounted for 85.2% of the isolates, which is in agreement to another study in China [12]. However, in the present study, the prevalence of serotype 15B/15C was unexpectedly high, accounting for 6.7% of the isolates, which was different from other studies [10–12], suggesting that 15B/15C is a common serotype in Shenzhen China and should be included in the screening test.

Table 2. Serotype Results Identified by MLPA-MC for 210 Pneumococcal Isolates.

| Serotype results | Positive isolates | Actual MC Results |
|------------------|-------------------|------------------|
|                  | no    | %     | Tm ±1 | Dye     |
| 19F              | 67    | 31.9  | 61    | ROX     |
| 23F              | 40    | 19.1  | 71    | ROX     |
| 19A              | 22    | 10.5  | 64    | CY5     |
| 6                | 37    | 17.6  | 64    | ROX     |
| 15B/15C          | 14    | 6.7   | 75    | CY5     |
| 14               | 13    | 6.2   | 54    | ROX     |
| 15F/15A          | 2     | 1.0   | 69    | CY5     |
| 4                | 1     | 0.5   | 75    | ROX     |
| 18               | 1     | 0.5   | 60    | CY5     |
| 9V/9A            | 1     | 0.5   | 53    | CY5     |
| cpsA             | 209   | 99.5  | 79    | CY5     |
| lytA             | 210   | 100   | 79    | ROX     |
| Non-typeable in this study | 12   | 5.7   | no serotype specific melting peak |

doi:10.1371/journal.pone.0130664.t002

Table 3. Comparison of MLPA-MC to mPCR reaction.

|                      | mPCR                      | MLPA-MC                      |
|----------------------|---------------------------|------------------------------|
| Target gene          | Serotype specific cps gene| Serotype specific cps gene   |
| PCR amplified template | Target DNA               | Specific MLPA probe          |
| PCR primer needed    | Multiplex serotype specific primers | A pair of universal primers |
| Discrimination of serotype by | Serotype specific primers | Serotype specific MLPA probes, serotype specific fluorescent detection probes |
| Reaction steps        | Multiplex PCR, electrophoresis, gel imaging, separately | Continuous reaction in one well: hybridization, ligation and PCR, melting curve analysis |
| PCR products size & type & detection by | 160–753 bp; dsDNA & electrophoresis | 109–136 bp; dsDNA, ssDNA; melting curve assay |
| Turn around time      | ~ 9 h                     | ~3 h                         |
| Analytic machines     | Thermal cycler; electrophoresis; Gel Imager | LightCycler 480 or other fluorescence reader |

doi:10.1371/journal.pone.0130664.t003
Our study has a limitation in that it could not determine the serotypes within serogroup 6, so we proposed using MLPA-MC as serogroup 6 screening assay, in line with USA CDC mPCR assays. Thereafter, published serotypes 6A-6D serotype-specific PCR would be used for further differentiation within serogroup 6 [15, 26, 27]. We have completed serotypes 6A/6B/6C/6D-specific PCR and the frequencies of serotypes 6A, 6B and 6C among 27 serogroup 6 isolates in the study were 44.4% (12/27), 48.1% (13/27) and 7.4% (2/27), respectively; serotype 6D was not found in the isolates. As the GenBank and PubMed analysis suggested that new serotypes 6E and 6F in serogroup 6 were still coming out, we intend to design a new MLPA-MC panel that focuses on serogroup 6 in the future when the serotypes in serogroup 6 are clearer.

In this study, we provide only one serotype/serogroup screening panel by using of MLPA-MC assay, but it can be easily adapted to suit other panels of serotypes. The whole reaction system can be easily repeated in different panels. Only modification of the LPO and RPO to target the new serotype/serogroup-specific cps sequence is required to complete design of a new serotype specific MLPA probe. Fluorescent detecting probes can be used repeatedly in different serotype panels. We have designed another 5 serotype specific MLPA probes for serotypes 1, 2, 3, 5, 7F/7A and listed as S1 Table. which would be a new panel, but need further comprehensive evaluation before clinical use. Later we plan to design more serotype specific MLPA probes to extend the system, with more MLPA-MC panels to be chosen.

We recommend using this MLPA-MC assay as a starting point for screening serotype/serogroup frequencies. This assay can be combined with other molecular typing assays or even the Quellung reaction for serotype confirmation, like for serotypes in serogroup 6. It can also be used for serotype determination in pure culture isolates as part of serotype surveillance studies before and after introduction of pneumococcal vaccination. By using the popular LightCycler 480, the MLPA-MC assay can be easily introduced to most clinical labs and readily assign results to 96 isolates in half a day with high throughput and little manual labour.

Supporting Information

S1 Fig. Representative multiplex PCR products patterns. (A) mPCR reaction one–for serotype 4, serogroup 6 and serogroup 18. (B) mPCR reaction two–for serotype 14, serotypes 9V/9A, serotypes 15F/15A and serotype 19A. (C) mPCR reaction three–for serotype 15B/15C, serotype 19F and serotype 23F.

(TIF)

S1 Table. The New Probes Details of the MLPA-MC Assay.

(DOC)

Author Contributions

Conceived and designed the experiments: LW LZ QW. Performed the experiments: LW XY YH. Analyzed the data: LW XY LZ FK PJ. Contributed reagents/materials/analysis tools: JZ QW XC FK YH. Wrote the paper: LW FK TK PJ QW. Isolated and collected the strains: LW JZ. Contributed clinical data: PJ XC.

References

1. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009; 374: 893–902. doi: 10.1016/S0140-6736(09)61204-6 PMID: 19749398

2. Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012; 25: 409–419. doi: 10.1128/CMR.00018-12 PMID: 22763632
3. Liu Y, Wang H, Chen M, Sun Z, Zhao R, Zhang L, et al. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn Microbiol Infect Dis. 2008; 61: 256–263. doi: 10.1016/j.diagmicrobio.2008.02.004 PMID: 18358662

4. Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother. 2012; 56: 1418–1426. doi: 10.1128/AAC.05658-11 PMID: 22232285

5. Dortet L, Ploy MC, Poyart C, Raymond J. Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis. 2009; 65: 49–57. doi: 10.1016/j.diagmicrobio.2009.05.009 PMID: 19679235

6. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006; 354: 1455–1463. PMID: 16598044

7. Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM, Parkhill J, et al. Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet. 2013; 45: 656–663. doi: 10.1038/ng.2625 PMID: 23644493

8. Tyrrell GJ. The changing epidemiology of Streptococcus pneumoniae serotype 19A clonal complexes. J Infect Dis. 2011; 203: 1345–1347. doi: 10.1093/infdis/jir056 PMID: 21938394

9. McEllistrem MC. Genetic diversity of the pneumococcal capsule: implications for molecular-based serotyping. Future Microbiol. 2009; 4: 857–865. doi: 10.2217/fmb.09.58 PMID: 19722839

10. Xue L, Yao K, Xie G, Zheng Y, Wang C, Shang Y, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates that cause invasive disease among Chinese children. Clin Infect Dis. 2010; 50: 741–744. doi: 10.1086/650534 PMID: 20113175

11. Yao KH, Wang LB, Zhao GM, Zheng YJ, Deng L, Huang JF, et al. Pneumococcal serotype distribution and antimicrobial resistance in Chinese children hospitalized for pneumonia. Vaccine. 2011; 29: 2296–2301. doi: 10.1016/j.vaccine.2011.01.027 PMID: 21276441

12. Ma X, Zhao R, Ma Z, Yao K, Yu S, Zheng Y, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing invasive diseases from Shenzhen Children’s Hospital. PLoS ONE. 2013; 8: e67507. doi: 10.1371/journal.pone.0067507 PMID: 23840728

13. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol. 2006; 44: 124–131. PMID: 16390959

14. Siira L, Kaijalainen T, Lambertsen L, Nahm MH, Toropainen M, Virolainen A. From Quellung to multiplex PCR, and back when needed, in pneumococcal serotyping. J Clin Microbiol. 2010; 48: 2727–2731. doi: 10.1128/JCM.00484-09 PMID: 20113175

15. Jin P, Xiao M, Kong F, Oftadeh S, Zhou F, Liu C, et al. Simple, accurate, serotype-specific PCR assay to differentiate Streptococcus pneumoniae serotypes 6A, 6B, and 6C. J Clin Microbiol. 2009; 47: 2470–2474. doi: 10.1128/JCM.00484-09 PMID: 19535528

16. Kong F, Brown M, Sabananthan A, Zeng X, Gilbert GL. Multiplex PCR-based reverse line blot hybridization assay to identify 23 Streptococcus pneumoniae polysaccharide vaccine serotypes. J Clin Microbiol. 2006; 44: 1887–1891. PMID: 16672432

17. Kong F, Wang W, Tao J, Wang L, Wang Q, Sabananthan A, et al. A molecular-capsular-type prediction system for 90 Streptococcus pneumoniae serotypes using partial cpsA-cpsB sequencing and wzy- or wzx-specific PCR. J Med Microbiol. 2005; 54: 351–356. PMID: 15770019

18. da Gloria Carvalho M1, Pimenta FC, Jackson D, Roundtree A, Ahmad Y, Millar EV, et al. Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes. J Clin Microbiol. 2010; 48: 1611–1618. doi: 10.1128/JCM.02243-09 PMID: 20220175

19. Schouten JP, McElgunn CJ, Waaier R, Zwijnenburg D, Dieuvens F, Pals G. Relative quantification of 40 nucelic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002; 30: e57 PMID: 12060695

20. Reijans M, Dingemans G, Klaassen CH, Meis JF, Keijdener J, Mulders B, et al. RespiFinder: a new multiparameter test to differentially identify fifteen respiratory viruses. J Clin Microbiol. 2008; 46: 1232–1240. doi: 10.1128/JCM.02294-07 PMID: 18256230

21. van Selim S, van Cann LM, Kolkman MA, van der Zeijst BA, van Putten JP. Genetic basis for the structural difference between Streptococcus pneumoniae serotype 15B and 15C capsular polysaccharides. Infect Immun. 2003; 71: 6192–6198. PMID: 14573636
22. Elberse K, Witteveen S, van der Heide H, van de Pol I, Schot C, van der Ende A, et al. Sequence diversity within the capsular genes of Streptococcus pneumoniae serogroup 6 and 19. PLoS ONE. 2011; 6: e25018. doi:10.1371/journal.pone.0025018 PMID: 21949837

23. Selva L, del Amo E, Brotons P, Munoz-Almagro C. Rapid and easy identification of capsular serotypes of Streptococcus pneumoniae by use of fragment analysis by automated fluorescence-Based capillary electrophoresis. J Clin Microbiol. 2012; 50: 3451–3457. doi:10.1128/JCM.01368-12 PMID: 22875895

24. Miernyk K, Debye C, Harker-Jones M, Hummel KB, Hennessy T, Wenger J, et al. Serotyping of Streptococcus pneumoniae isolates from nasopharyngeal samples: use of an algorithm combining microbiologic, serologic, and sequential multiplex PCR techniques. J Clin Microbiol. 2011; 49: 3209–3214. doi:10.1128/JCM.00610-11 PMID: 21775540

25. Azzari C, Moriondo M, Indolfi G, Cortimiglia M, Canessa C, Becciolini L, et al. Realtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in children with culture negative pneumococcal invasive disease. PLoS One. 2010; 5: e9282. doi:10.1371/journal.pone.0099282 PMID: 20174571

26. Jin P, Kong F, Xiao M, Oftadeh S, Zhou F, Liu C, et al. First report of putative Streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from Fijian children. J Infect Dis. 2009; 200: 1375–1380. doi:10.1086/606118 PMID: 19803727

27. Thomas JC, Kong Y, Sabharwal V, Pelton SI, Pettigrew MM. Streptococcus pneumoniae serotype 6C: an intra- and inter-clonal complex comparison. J Bacteriol. 2011; 193: 3409–3410. doi:10.1128/JB.05079-11 PMID: 21551297